GenMark Diagnostics (GNMK)
GenMark Diagnostics Revenue Growth: 158.4%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GNMK Revenue Growth Rankings
| Overall | 98th percentile | 83 of 4357 |
| Sector | 94th percentile | 27 of 456 in Healthcare |
| Industry | 97th percentile | 2 of 74 in Medical Appliances & Equipment |
GNMK Revenue Growth Range, Past 5 Years
| Minimum | 38.40% | Jun 2011 |
| Maximum | 161.4% | Jun 2010 |
| Average | 122.1% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these GNMK related companies
GNMK News
GenMark Diagnostics Schedules First Quarter 2012 Financial Results and Conference Call for May 8, 2012
Apr 27, 9:00AM Business Wire
Apr 27, 9:00AM Business Wire
Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
Apr 18, 10:25AM Street Insider
Apr 18, 10:25AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Opportunities Hold Promise
Apr 17, 8:27AM Street Insider
Apr 17, 8:27AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Positive on New CFO & Deal with PerkinElmer (PKI)
Apr 04, 9:03AM Street Insider
Apr 04, 9:03AM Street Insider
GenMark Enters into License Agreement with PerkinElmer for Microfluidics Patent Portfolio
Mar 29, 6:00AM Business Wire
Mar 29, 6:00AM Business Wire
URGENT: $GNMK filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/2tXy
about 75 days ago by MarketBrief
about 75 days ago by MarketBrief
GenMark Diagnostics Reports Final Fourth Quarter and Fiscal Year 2011 Results
Mar 15, 6:00AM Business Wire
Mar 15, 6:00AM Business Wire
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Pipeline Looking Good
Mar 09, 10:24AM Street Insider
Mar 09, 10:24AM Street Insider
GenMark Diagnostics Reports Preliminary Fourth Quarter and Fiscal Year 2011 Results
Mar 08, 4:00PM Business Wire
Mar 08, 4:00PM Business Wire
GenMark Diagnostics Appoints Dr. Jorge Garces Senior Vice President, Research and Development
Feb 16, 6:00AM Business Wire
Feb 16, 6:00AM Business Wire
GenMark Diagnostics Schedules Third Quarter 2011 Financial Results and Conference Call for November 10, 2011
Oct 28, 8:30PM Business Wire
Oct 28, 8:30PM Business Wire
$GNMK
GenMark Diagnostics Gas Reports Q2 EPS $(0.39) vs $(0.53) Est; Revenues $901K vs $860.00K Est
about 299 days ago by Benzinga
about 299 days ago by Benzinga
$GNMK Prices public offering of 7M shares at $4.25/shr
Granted the underwriters an option to purchase up to an additional 1,059,840 shares
about 348 days ago by bricktop13
about 348 days ago by bricktop13
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GNMK | 4.61 | +0.03 | +0.66% | 93.89M |
| GNK | 3.23 | +0.01 | +0.31% | 141.07M |
| GNI | 65.28 | +2.39 | +3.80% | 94.34M |
| GNE | 7.07 | +0.06 | +0.86% | |
| GNCMA | 6.33 | -0.36 | -5.38% | 295.30M |
| GNC | 39.54 | -0.01 | -0.03% | |
| GNAT | 21.95 | +0.36 | +1.69% | |
| GMXR | 0.95 | +0.03 | +3.26% | 62.81M |
| GMT | 38.98 | +0.31 | +0.80% | 1.811B |
| GMO | 2.61 | +0.10 | +3.98% | 228.86M |
